Combigan and Iobenguane I-131
Determining the interaction of Combigan and Iobenguane I-131 and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Timolol ophthalmic may interfere with the effects of iobenguane I-131 in treating your condition. Let your doctor know you are receiving or have recently received timolol ophthalmic if you are being prescribed iobenguane I-131. You may need to stop using timolol ophthalmic for a certain amount of time before and after starting treatment with iobenguane I-131. Talk to your doctor if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:GENERALLY AVOID: Coadministration with drugs that reduce catecholamine uptake or deplete catecholamine stores may interfere with iobenguane I-131 uptake into neuroendocrine tumors such as pheochromocytoma and paraganglioma that express high levels of norepinephrine transporter on their cell surfaces. Since iobenguane is similar in structure to norepinephrine and is subject to the same uptake and accumulation pathways as norepinephrine, drugs that alter norepinephrine disposition in adrenergic nerve terminals and presynaptic storage vesicles will likewise affect iobenguane. Dosimetry calculations and efficacy of iobenguane I-131 may be altered. These drugs include central nervous system stimulants (e.g., amphetamines, cocaine, methylphenidate); norepinephrine and dopamine reuptake inhibitors (e.g., phentermine); norepinephrine and serotonin reuptake inhibitors (e.g., tramadol); central monoamine depleting drugs (e.g., reserpine); nonselective beta-adrenergic blockers (e.g., labetalol); alpha agonists or alpha/beta agonists (e.g., pseudoephedrine, phenylephrine, ephedrine, phenylpropanolamine, naphazoline); monoamine oxidase inhibitors; tricyclic antidepressants; norepinephrine reuptake inhibitors (e.g., bupropion, duloxetine, mirtazapine, venlafaxine); and botanicals that may inhibit reuptake of norepinephrine, serotonin, or dopamine (e.g., ephedra, ma huang, St John's wort, yohimbine). These drugs were not permitted in clinical trials that assessed the safety and efficacy of iobenguane I-131.
MANAGEMENT: Drugs that reduce catecholamine uptake or deplete catecholamine stores should be discontinued for at least five biological half-lives before administration of either the dosimetry dose or a therapeutic dose of iobenguane I-131. Do not administer these drugs until at least 7 days after each iobenguane I-131 dose. Patients should be monitored for the occurrence of clinically significant withdrawal symptoms, especially patients with elevated levels of circulating catecholamines and their metabolites.
- "Product Information. Azedra (iobenguane I-131)." Progenics Pharmaceuticals, Inc., New York, NY.
Generic Name: brimonidine / timolol ophthalmic
Brand name: Combigan
Synonyms: n.a.
Generic Name: iobenguane I 131
Brand name: AdreView, Azedra
Synonyms: Iobenguane I 131
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Combigan-Iodex Topical
- Combigan-Iodine
- Combigan-Iodine and potassium iodide (strong iodine)
- Combigan-Iodine Topical
- Combigan-Iodipamide Meglumine
- Combigan-Iodixanol
- Iobenguane I-131-CombiPatch
- Iobenguane I-131-Combipatch transdermal
- Iobenguane I-131-Combivent
- Iobenguane I-131-Combivent Respimat
- Iobenguane I-131-Combivent Respimat inhalation
- Iobenguane I-131-Combivir